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Novel attributes of Locked Nucleic Acid (LNA) makes it preferable over most of the other classes of modified
nucleic acid analogues and therefore, it has been extensively explored in different synthetic oligonucleotide
based therapeutics. In addition to five oligonucleotides of this class undergoing clinical trials, a healthy pipeline
in pre-clinical studies validates the tenacity of LNA. Due to the increasing demand, an efficient biocatalytic methodology
has recently been devised for the convergent synthesis of LNA monomers via selective enzymatic monoacetylation of
diastereotopic hydroxymethyl functions of 3-O-benzyl-4-C-hydroxymethyl-1,2-O-isopropylidene-α-D-ribofuranose. This
commentary article provides an insight into the different synthetic strategies followed for the synthesis of LNA
monomers and their triumphs in clinical biotechnology.
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Linear synthesis, Convergent synthesis, MiravirsenSince the acclamation of nucleic acid therapeutics,
modification in the sugar moiety of nucleosides has
continuously reflected its supremacy for developing
drug candidates for the treatment of cancer and viral
infections [1-3]. After the pioneering development in
dideoxy- and acyclic- nucleos(t)ides [3], currently the
most promising modification in the ribofuranose moiety
has appeared through the inclusion of an extra methylene
bridge between 2′-O & 4′-C atom and synthesis of oli-
gonucleotides (ONs) involving the modified nucleo-
sides, termed as locked nucleic acid (LNA) (Figure 1)
[4,5]. Although, no significant potency was observed
against cancer or viral infections by LNA monomers
or its analogues [6]; there is hardly any synthetic
oligonucleotide (ON) based therapeutic strategy which
has not been allured by their unique features [4,5,7,8].
Seminal papers on LNA were independently insti-
gated by Wengel [9,10] and Imanishi [11] groups. It is
well known that the B-form DNA duplex possesses
C2′-endo (S-type) and the A-form RNA duplex has C3′-
endo (N-type) sugar puckering [12,13]. LNA is consid-
ered to be RNA mimic as the ancillary methylene
bridge locks the sugar moiety into N-type sugar ring* Correspondence: ashokenzyme@gmail.com
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unless otherwise stated.conformation (Figure 1). This conformational restriction
results in preorganization of the backbone of LNA ONs,
which leads to energetically favorable duplex formation via
increased base stacking interactions according to standard
Watson-Crick base pairing rules [14]. Generally, the melt-
ing temperature (Tm) of duplexes is raised by 2-8°C per
LNA nucleotide incorporation when compared to the
corresponding unmodified duplexes, depending on the
sequence context and number of modifications [14-16].
This makes LNA the prime nucleotide modification
candidate for the applications where high hybridization
affinity is desirable.
LNA-modified ONs have been extensively utilized in
different approaches to target the corresponding nucleic
acid counterparts. These primarily include, (a) antigene
approach to block transcription of a particular gene; (b)
antisense approach to induce RNA degradation; (c)
siRNA mediated RNA degradation; and (d) blocking of
microRNA [7,8]. Since LNA possess high hybridization
affinity and target selectivity, it is unsurprising that
increasing success in cell-line based experiments has
paved their way to five LNA-based modified ONs under
active clinical trials (Table 1). One of the most advanced
LNA-based drugs Miravirsen which has entered Phase II
clinical study is being developed by Santaris Pharma A/S.
Miravirsen is an inhibitor of miR-122, a liver specificis an open access article distributed under the terms of the Creative Commons
org/licenses/by/4.0), which permits unrestricted use, distribution, and
riginal work is properly credited. The Creative Commons Public Domain






































Figure 1 Structure and conformations of DNA, RNA and LNA;
B = nucleobase.
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replication. The liver-expressed miR-122 protects HCV
from degradation. Miravirsen is designed to recognize and
sequester miR-122, making it unavailable for HCV. As a re-
sult, the replication of the virus is effectively inhibited and
the level of HCV is profoundly reduced (Figure 2) [17]. If
its phase III trial looks anything like its phase II, Miravirsen
could be the first LNA-based drug to get FDA approval.Table 1 Current clinical trials of oligonucleotides modified wi
S.no. LNA modified oligonucleotide Indication
1 Miravirsen (SPC-3649) Hepatitis C virus (HCV
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Figure 2 Mechanism of action of chemically modified drug MiravirsenTwo general strategies have been employed for the
synthesis of LNA monomers; a linear strategy using
commercially available RNA nucleosides as the starting
material [11,19] and a convergent strategy where a
common glycosyl donor is synthesized for coupling
with different nucleobases [10,20,21]. Linear strategy
was disclosed by Obika et al. [11] for the synthesis of
LNA-U monomer 1a with uridine (2) as the starting
material (Scheme 1).
Following similar strategy, Koshkin et al. [19] synthe-
sized LNA-A monomer taking adenosine as the starting
material. Despite having some advantages, such as
cheap and readily available RNA nucleosides as starting
material and short synthetic route to LNA monomers,
the linear approach suffers from poor yields. The two
key reactions in the synthetic pathway, i.e. the intro-
duction of the additional hydroxymethyl group at the
C-4′-position of the protected RNA nucleoside 4 and
the regioselective tosylation of the introduced 4′-C-hy-
droxymethyl group, generally proceeds with very low
yields (Scheme 1).
Alternatively, in the quest to establish a general method for
the synthesis of all LNA monomers i.e. LNA-U, 1a; LNA-T,
1b; LNA-A, 1c and LNA-C, 1d; the convergent strategy was
explored by Koshkin et al. [10] using 3-O-benzyl-4-C-hy-
droxymethyl-1,2-O-isopropylidene-α-D-ribofuranose (10) asth LNA [18]
Target Clinical phase
) MicroRNA-122 II
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Scheme 1 Linear synthesis of LNA-U monomer [11]. Reagents (% yields): (i) Cyclohexanone, PTSA (quantitative); (ii) 2-iodobenzoic acid, CH3CN
(76%); (iii) (a) 37% HCHO, 2N NaOH, 1,4-dioxane; (b) NaBH4 (38%); (iv) (a) TsCl, Pyridine; (b) TFA, water (34%); (v) PhCHO, ZnCl2, (80%); (vi) NaBH3CN,
TiCl4, CH3CN (75%); (vii) NaHMDS, THF (61%); (viii) 10% Pd-C, H2, MeOH (quantitative).
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D-glucose [22,23]. Regioselective 5-O-benzylation of 10
followed by acetolysis afforded the furanose 12 in 55%
yield, a key intermediate for coupling reactions with a var-
iety of nucleobases. The Vorbrüggen coupling with sily-
lated nucleobases afforded the nucleosides 13a-d, which
on deacetylation led to the formation of benzylatedScheme 2 Convergent synthesis of LNA monomers [10]. Reagents (% y
(c) Ac2O, Pyridine (77%); (iii) nucleobase, N,O-bis(trimethylsilyl)acetamide, TMS-
74%); (iv) NaOMe, MeOH (14a, 95%; 14b, 97%; 14c, 73%; 14d, 54%); (v) (a) TsC
20% Pd(OH)2-C, H2, EtOH (1a, 78%; 1b, 98%); BCl3, DCM (1c, 84%); 10% Pd-C, 1
Scheme 3 Improved convergent synthesis of LNA monomers [20,21].
conc. H2SO4 (97%); (iii) nucleobase, N,O-bis(trimethylsilyl)acetamide, TMS-trif
82%); (iv) aq. NaOH, THF or dioxane (19a, 97%; 19b, 94%; 19c, 78%; 19d, 8
NaOH, THF (9a, 95%; 9b, 91%); NH4OH, MeOH (9c, 86%); (a) 20% Pd(OH)2-C
HCOOH, THF/MeOH (9:1) (1a, 91%); 20% Pd(OH)2-C, HCO2NH4, MeOH or Etnucleosides 14a-d. The tosylation of the primary hy-
droxyl group in benzylated nucleosides 14a-d followed
by in situ base-induced intramolecular ring closure
afforded the 2′-O,4′-C-linked locked nucleoside deriva-
tives 15a-d. Debenzylation on dibenzylated nucleosides
15a-d efficiently yielded the LNA monomers 1a-d
(Scheme 2).ields): (i) BnBr, NaH, DMF (71%); (ii) (a) Ac2O, Pyridine; (b) 80% AcOH;
triflate, CH3CN or 1,2-dichloroethane (13a, 75%; 13b, 76%; 13c, 52%; 13d,
l, Pyridine; (b) NaH, DMF (15a, 30%; 15b, 42%; 15c, 44%; 15d, 51%); (vi)
,4-cyclohexadiene, MeOH (1d, 36%).
Reagents (% yields): (i) MsCl, pyridine, CH2Cl2 (98%); (ii) Ac2O, AcOH,
late, CH3CN or 1,2-dichloroethane (18a, 90%; 18b, 88%; 18c, 68%; 18d,
7%); (v) NaOBz, DMF (20a, 97%; 20b, 86%; 20c, 88%; 20d, 93%); (vi) aq.
, HCO2NH4, MeOH; (b) NH4OH (1d, 77%); (vii) 20% Pd(OH)2-C, 88%
OH (1b, 83%; 1c, 91%).
Scheme 4 Novozyme®-435 mediated monoacetylation of diol
10 [24].
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synthesis of LNA monomers with all natural nucleo-
bases was standardized, regioselective benzylation of
dihydroxy furanose derivative 10 remained unanswered
[10]. Hence, in order to avoid the regioselective trans-
formation on the furanose diol 10, an alternate conver-
gent synthesis was optimized by Koshkin et al. [20]
(Scheme 3). Permesylation of furanose diol 10 afforded
the dimesylated derivative 16, which on acetolysis
followed by acetylation, afforded an anomeric mixture
of 1,2-di-O-acetyl-3-O-benzyl-4-C-methanesulfonyloxy-
methyl-5-O-methanesulfonyl-D-ribofuranose (17). The
glycosyl donor 17 was used as a common intermediate
for coupling reactions with different nucleobases to
afford the LNA monomers 1a-d [20,21] as shown in
Scheme 3.
It seems easy to synthesize LNA monomers following
the convergent strategy which utilizes the furanose diol
10 as the starting material. However, the use of 10 was
found to be complicated due to the presence of two
diastereotopic hydroxymethyl groups (Scheme 2 and
Scheme 3). Therefore, we focused our attention towards
lipase mediated diastereoselective protection of one of
the hydroxymethyl groups in the crucial intermediate
10 with a base labile group such as acetyl, that can
be hydrolyzed insitu concomitantly with 2′-O,4′-C-
































Figure 3 Study of recyclability of lipase Novozyme®-435 for acetylatio
mg batch size w.r.t. 10).LNA monomers [24]. Screening of different lipases in
organic solvents for the diasteroeselective acetylation of
one of the two hydroxyl groups in dihydroxy compound
3-O-benzyl-4-C-hydroxymethyl-1,2-O-isopropylidene-α-
D-ribofuranose (10) revealed that Candida antarctica
lipase-B (Novozyme®-435) in diisopropyl ether (DIPE)
in the presence of vinyl acetate as acetyl donor carries
out the selective 5′-O-monoacetylation (Scheme 4).
In a successful biocatalytic transformation reaction, a
solution of the compound 10 and vinyl acetate in DIPE
was incubated with Novozyme®-435 (10% w/w of 10) at
45°C and 200 rpm in an incubator shaker. The progress
of the reaction was monitored on analytical TLC. On
completion, reaction was quenched by filtering off the
enzyme and solvent was removed under reduced pressure.
The crude product thus obtained was washed with hexane
to afford monoacetylated compound 5-O-acetyl-3-O-ben-
zyl-4-C-hydroxymethyl-1,2-O-isopropylidene-α-D-ribofur-
anose (21) in quantitative yield. Using the optimized
conditions, Novozyme®-435 was utilised for ten recycles of
selective acetylation of compound 10 and was found to be
equally regioselective for each cycle (Figure 3).
The synthesis of LNA monomers 1a-d was successfully
achieved from enzyme-mediated monoacetylated com-
pound 21. Tosylation of 21 afforded compound 22 which
on subsequent acetolysis gave an anomeric mixture 23 in
95% overall yield. Aiming for the convergent synthesis of
LNA monomers, the mixture 23 was used as common
glycosyl donor for the Vorbrüggen’s coupling reaction with
uracil, thymine, 6-N-benzoyladenine and cytosine to yield
the corresponding 2′,5′-di-O-acetyl-3′-O-benzyl-4′-C-p-
toluenesulfonyloxymethyl-ribonucleosides 24a-d in 71-
89% yields. Subsequently, deacetylation and concomitant
intramolecular cyclization under alkaline conditions
afforded the 3′-O-benzyl-2′-O,4′-C-methylene-ribonucleo-


























n reaction on diol 10. (All these reactions were performed on 100
Scheme 5 Chemo-enzymatic convergent synthesis of 2'-O,4'-C-
methylene-ribonucleosides (LNA monomers) 1a-d [24]. Reagents
& conditions (% yields): (i) TsCl, pyridine, CH2Cl2, 0°C to rt (98%);
(ii) Ac2O, AcOH, H2SO4 (100:10:0.1), 0°C to rt (97%); (iii) nucleobase,
N,O-bis(trimethylsilyl) acetamide, TMS-triflate, acetonitrile or 1,2-
dichloroethane, 80°C (24a, 89%; 24b, 88%; 24c, 71%; 24d, 78%);
(iv) aq. NaOH, 1,4-dioxane, rt (+NH4OH for 9c) (9a, 95%; 9b, 93%; 9c,
89%; 9d, 94%); (v) 20% Pd(OH)2-C, HCOOH, THF:MeOH (9:1), reflux
(1a, 91%); 20% Pd(OH)2-C, HCO2NH4, MeOH or EtOH, reflux (1b, 83%;
1c, 91%; 1d, 81%).
Sharma et al. Sustainable Chemical Processes  (2015) 3:2 Page 5 of 6benzyl group in nucleosides 9a-d afforded the LNA mono-
mers, i.e. 2′-O,4′-C-methyleneuridine (1a), 2′-O,4′-C-
methylenethymidine (1b), 2′-O,4′-C-methyleneadenosine
(1c) and 2′-O,4′-C-methylenecytidine (1d) in 81-91%
yields (Scheme 5).
Starting from the diol 10, the overall yields for devel-
oped chemo-enzymatic convergent synthesis of LNA
monomers (Scheme 5) have been compared with the lit-
erature convergent methodology (Scheme 3). The results
revealed that the developed biocatalytic methodology is
more efficient in all cases with remarkable improvement
for LNA-A (Table 2).Conclusion
Unprecedented success of Locked Nucleic acid (LNA) in
oligonucleotide based therapeutics demands a cost effi-
cient, convenient and environment friendly synthetic route
for LNA monomers. Therefore, Novozyme®-435 mediated
selective protection of 3-O-benzyl-4-C-hydroxymethyl-1,2-
O-isopropylidene-α-D-ribofuranose has been highlighted
which lead to relatively efficient and environment friendly
synthesis of LNA monomers in comparison to the earlier
reports.Table 2 Overall yields of LNA monomers for the reported
classical chemical and chemo-enzymatic convergent
synthesis




U; 1a 69.6 72.4
T; 1b 51.1 63.9
A; 1c 34.7 54.1
C; 1d 48.6 55.9
*The overall yields have been calculated from dihydroxy compound 10.Abbreviations
LNA: Locked nucleic acid; ON: Oligonucleotide; HCV: Hepatitis C virus;
DIPE: Diisopropyl ether.
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